Mabthera®(Non-English)

MabThera® (Rituximab) is a monoclonal antibody used to treat autoimmune diseases and specific types of cancers, including non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and moderate to severe rheumatoid arthritis (RA). It works by targeting and eliminating CD20-positive B cells, a type of white blood cell involved in these diseases. By reducing abnormal B cells, MabThera® helps slow disease progression, manage symptoms, and improve patient outcomes.

This therapy is typically administered intravenously under professional supervision and may be used alone or in combination with other treatments, such as chemotherapy or immunotherapy, depending on the condition. MabThera® has shown to improve remission rates in cancer and reduce inflammation and joint damage in RA when other treatments are insufficient.

MabThera® is commonly used by hematologists, oncologists, rheumatologists, and other medical professionals seeking targeted, effective therapy for B-cell-related conditions, and requires careful monitoring due to its immune-modulating effects.

Disclaimers:

– For administration by trained healthcare professionals only. Use requires medical supervision to ensure proper dosing, monitoring, and management of potential side effects.

– Patients must be screened for active infections, including hepatitis B, before initiating therapy to avoid serious complications.

– Not recommended for individuals with severe active infections or known hypersensitivity to rituximab without thorough medical evaluation.

– Usage should follow local medical guidelines and approved protocols for treating autoimmune diseases and cancers.